WO2003060142A3 - Compositions and methods for controlled release - Google Patents

Compositions and methods for controlled release Download PDF

Info

Publication number
WO2003060142A3
WO2003060142A3 PCT/US2002/033558 US0233558W WO03060142A3 WO 2003060142 A3 WO2003060142 A3 WO 2003060142A3 US 0233558 W US0233558 W US 0233558W WO 03060142 A3 WO03060142 A3 WO 03060142A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
compositions
methods
controlled release
scaffold
Prior art date
Application number
PCT/US2002/033558
Other languages
French (fr)
Other versions
WO2003060142A9 (en
WO2003060142A2 (en
Inventor
Arthur H Wong
Jacob M Waugh
Michael D Dake
Original Assignee
Essentia Biosystems Inc
Arthur H Wong
Jacob M Waugh
Michael D Dake
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentia Biosystems Inc, Arthur H Wong, Jacob M Waugh, Michael D Dake filed Critical Essentia Biosystems Inc
Priority to AU2002365136A priority Critical patent/AU2002365136A1/en
Priority to EP02803289A priority patent/EP1446008A4/en
Priority to JP2003560224A priority patent/JP2005523890A/en
Priority to CA002464131A priority patent/CA2464131A1/en
Publication of WO2003060142A2 publication Critical patent/WO2003060142A2/en
Publication of WO2003060142A9 publication Critical patent/WO2003060142A9/en
Publication of WO2003060142A3 publication Critical patent/WO2003060142A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Methods and compositions are provided for the controlled release of an active agent. The composition includes an oligonucleotide scaffold and a substantially complementary oligonucleotide factor. An active agent is attached to the oligonucleotide factor. The two oligonucleotides are differentially degradable, so that degradation of the scaffold occurs a faster rate than the degradation of the factor. As the scaffold degrades, the factor is released. The active agent can be a therapeutic agent, or a diagnostic agent.
PCT/US2002/033558 2001-10-18 2002-10-17 Compositions and methods for controlled release WO2003060142A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002365136A AU2002365136A1 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release
EP02803289A EP1446008A4 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release
JP2003560224A JP2005523890A (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release
CA002464131A CA2464131A1 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33634401P 2001-10-18 2001-10-18
US60/336,344 2001-10-18

Publications (3)

Publication Number Publication Date
WO2003060142A2 WO2003060142A2 (en) 2003-07-24
WO2003060142A9 WO2003060142A9 (en) 2003-08-21
WO2003060142A3 true WO2003060142A3 (en) 2004-02-12

Family

ID=23315656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033558 WO2003060142A2 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Country Status (5)

Country Link
EP (1) EP1446008A4 (en)
JP (1) JP2005523890A (en)
AU (1) AU2002365136A1 (en)
CA (1) CA2464131A1 (en)
WO (1) WO2003060142A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145813A1 (en) 2008-03-04 2009-12-03 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
WO2011031871A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
WO2011031876A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations including nanoparticles
DE102009058769A1 (en) * 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperature-dependent activation of catalytic nucleic acids for controlled drug release
JP2016183434A (en) * 2015-03-26 2016-10-20 国立大学法人京都大学 Surface modification substrate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050462A1 (en) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985554A (en) * 1994-11-02 1999-11-16 Takeda Chemical Industries, Ltd. Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides
PL337033A1 (en) * 1997-05-21 2000-07-31 Univ Leland Stanford Junior Composition for and methods of enhancing transport through permeable biological membranes
WO2000041732A1 (en) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
AU1072801A (en) * 1999-10-01 2001-05-10 Essentia Biosystems, Inc. Gel-forming compositions
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc
US20030134811A1 (en) * 2001-10-09 2003-07-17 John Jackson Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050462A1 (en) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POTAMAN ET AL.: "Site-specific labeling of supercoiled DNA at the A+T rich sequences", BIOCHEMISTRY, vol. 41, 2002, pages 13198 - 13206, XP002973163 *
SAKHAROV ET AL.: "Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wall", ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 21, 2001, pages 943 - 948, XP001120149 *

Also Published As

Publication number Publication date
EP1446008A4 (en) 2006-08-16
WO2003060142A9 (en) 2003-08-21
WO2003060142A2 (en) 2003-07-24
AU2002365136A1 (en) 2003-07-30
EP1446008A2 (en) 2004-08-18
AU2002365136A8 (en) 2003-07-30
JP2005523890A (en) 2005-08-11
CA2464131A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2001049258A3 (en) Methods and compositions for improved delivery devices
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2000041528A3 (en) Improved controlled release compositions and method
WO2003000237A8 (en) Biodegradable polymer coompositions
WO2007081579A3 (en) Foam/spray producing compositions and dispensing system therefor
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
WO2007048219A3 (en) Sustained drug release composition
WO2004043432A3 (en) Controlled release depot formulations
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2007100776A3 (en) Antimicrobial compositions and methods for locking catheters
CA2320259A1 (en) Bioactive agent release coating
WO2005009357A3 (en) Controlled release compositions
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
BR0007360A (en) Controlled release composition
WO2007053578A3 (en) Multi-phasic nitric oxide and drug co-eluting stent coatings
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
WO2004034975A3 (en) Sustained release profile modification
WO2004004636A3 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003560224

Country of ref document: JP

Ref document number: 2464131

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002803289

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002803289

Country of ref document: EP